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Abstract
Recent research has revealed various molecular markers in lung cancer. However, the organizational principles underlying
their genetic regulatory networks still await investigation. Here we performed Network Component Analysis (NCA) and
Pathway Crosstalk Analysis (PCA) to construct a regulatory network in human lung cancer (A549) cells which were treated
with 50 uM motexafin gadolinium (MGd), a metal cation-containing chemotherapeutic drug for 4, 12, and 24 hours. We
identified a set of key TFs, known target genes for these TFs, and signaling pathways involved in regulatory networks. Our
work showed that putative interactions between these TFs (such as ESR1/Sp1, E2F1/Sp1, c-MYC-ESR, Smad3/c-Myc, and
NFKB1/RELA), between TFs and their target genes (such as BMP41/Est1, TSC2/Myc, APE1/Sp1/p53, RARA/HOXA1, and SP1/
USF2), and between signaling pathways (such as PPAR signaling pathway and Adipocytokines signaling pathway). These
results will provide insights into the regulatory mechanism of MGd-treated human lung cancer cells.
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Introduction
Lung cancer is a worldwide leading cause of cancer-related
death with a 5-year survival rate of less than 15% [1]. Several
molecular markers associated with lung cancer progression have
been identified, including TGF, MET, TP53, HIF1A, APC,
KRAS, and EGFR [2].
Transcription factors (TFs) and pathways play critical roles in
etiologies of lung cancer. For example, the transcription factor
E2F-1 is over-expressed in lung cancer cell, and the level is
enhanced by deregulated pRb-p53-MDM2 circuitry [3]. Tran-
scriptional regulation analysis has shown that the promoter activity
and expression level of Sp1 are regulated by Ets-1 in A549 lung
cancer cells. Functional analysis of two Ets-1-binding sites in Sp1
promoter suggests that only Ets-1-binding site 2413 to 2404 is
involved in the activation of Sp1 promoter [4]. It has also been
well-documented that the expression of cPLA2 is critical for the
transformed growth of lung cancer and for phorbol 12-myristate
13-acetate (PMA)-activated signal transduction pathway which is
involved in enzymatic activation of cPLA2. Studies reveal that c-
Jun/nucleolin and c-Jun/Sp1 complexes play an important role in
PMA-regulated cPLA2a gene expression [5]. In addition, several
pathways involved in lung cancer progression have been
demonstrated, such as PI3K/AKT pathway, TGF-beta signaling
pathway, Wnt pathway, JAK/STAT pathway, and MAPK/ERK
pathway [6,7,8,9].
High-throughput techniques in biology, such as microarray,
have generated a large amount of data that can potentially provide
systems-level information regarding the underlying dynamics
mechanisms [10]. To extract meaningful information (TFs and
pathways information) from high-throughput expression data, we
employed NCA and PCA to construct and analyze the dynamic
regulatory network in MGd-treated human lung cancer cells.
NCA, developed by James Liao [10], is a network structure-
driven framework for deducing regulatory signal dynamics. NCA
models the expression of a gene as a linear combination of the
activity of each transcription factor that controls the expression of
the gene. NCA makes use of the connectivity structure from
transcriptional regulatory networks and a set of gene expression
data to infer dynamics of transcription factor activities. NCA has
been successfully applied in inferring a transcriptional regulatory
network of the cytokinesis-related genes [11] and phase-specific
control elements of its cell cycle in yeast [12]. In this study, we
built an integrated dynamic model of the human lung cancer in
response to MGd, which consisted of the calculated transcription
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e31984factor activities, transcription factor regulatory influences on each
gene.
Given the complex nature of biological systems, more than one
pathway may be involved in any given complex disease. Two or
several pathways may interact with each other to cause the disease.
This is very likely because functional important proteins may be
involved in multiple pathways [13]. Therefore, besides the
identification of specific pathways, we also take a further step by
exploring the interaction and crosstalk between pathways that
related to MGd-treated lung cancer. In this study, we used a
computational approach to detect crosstalk among pathways based
on a protein-protein interaction (PPI) network, the co-expressed
significance of each gene pair, and a scoring scheme which is used
to define a function [14].
We defined the dynamic regulated network using NCA which
requires two inputs: a set of gene expression profiles and a pre-
defined matrix containing the influence of each transcription
factor on its estimated or identified target genes. Two outputs of
NCA (predicted factor activities and regulatory influences) have
added additional insights to gene expression data where the
underlying regulatory network structure is partially known. In
order to interpret transcription factor activities and regulation
strength(influences), the correction between TF activities and
expression, hierarchical clustering were calculated. Finally, the
dynamic regulated networks were constructed. Beside, PCA was
used to detect the relationship among pathways.
In brief, our study aims to reveal molecular mechanism of
MGd-treated human lung cancer cells from a dynamic and
systematic perspective by PCA and NCA. Our results should
provide new avenues for more advanced investigation into the
biological role of TFs and pathways in MGd-treated human lung
cancer cells.
Methods
Human lung cancer (A549) cells [15] were treated with 50 uM
metal cation-containing chemotherapeutic drug motexafin gado-
linium (MGd) for 4, 12, or 24 hours. Their expression profiles were
compared with those of the control cells treated by 5% mannitol
with the same incubation time. The detail of the samples was
shown in Table 1. The limma method [16] was used to identify
differentially expressed genes (DEGs) in the expression profile
(GSE2189). The DEGs with fold change .1.5 and p-value ,0.05
were selected for further analysis. Each selected DEG must be
differently expressed in more than one stage. In addition, 6328
regulatory relationships between 250 TFs and 2255 target genes
were collected from TRED [17] and TRANSFAC [18].
In order to add more regulation relationships between TF and
target genes, a total of 250 TFs and 144 DEGs were selected to be
hierarchically clustered by hcluster of R language. For each pair of
TF and its target gene, only the target gene in the sub-tree of the
TF-node with a coefficient larger than 0.8 (threshold |r|.0.8) was
selected for NCA.
Finally, 627 TF-target genes regulation relationships (contain-
ing the TF-TF interactions) were identified based on 164 TFs and
83 DEGs.
Network Component Analysis
NCA uses the standard log-linear model to approximate the
relationship between levels of TFs activity and that of the target-
gene expression by assuming the Hill cooperation between TFs on
the promoter region of target genes. Formally,
Ei(t)
Ei(0)
~ P
L
j~1
TFAj(t)
TFAj(0)
   CSij
ð1Þ
where t represents the time stage, Ei(t) is the gene expression level
and TFAj(t) is TF j’s activities and CSij reflects the control
strength of TF j on gene i.
Then, the equation (1) is linearized as (in matrix form):
log½Er ~½CS log½TFAr ð 2Þ
The matrix ½Er  consists of elements ½Er ij =Eij(t)=Eij(0), and
similarly ½TFAr ij = TFAij(t)=TFAij(0) represents the relative
gene expression levels and TFs’ activities. The dimension of ½Er  is
N|M(N genes and M samples or conditions) while that of ½TFAr 
is L|M(L TFs). They respectively indicate the time courses of
relative gene expression levels and TFs’ activities. Finally, the size
of ½CS  is N|L, which is the control strength for L TFs on each of
N genes. The equation (2) above can be further simplified as:
½E ~½S ½A ð 3Þ
Here, we have the strength matrix,½S , which corresponds to the
term of ½CS  in equation (2) and the TFs’ activity matrix½A , which
is the equivalent of log½TFAr  in the equation (2), and finally, the
gene expression matrix of ½E  corresponding to the term of log½Er 
in equation (2).
Based on the above preparation, the decomposition of ½E  into
½S  and ½A  can be achieved by minimizing the following object
function:
minDD(½E {½S ½A )DD ð4Þ
Subject to. S[Z0
In NCA, the above target function is estimated by using the
bootstrap algorithm and the value of ½S  and ½A  can be
normalized through a nonsingular matrix of ½X  according to
½E ~½S ½A ~½S ½X ½X{1 ½A ð 5Þ
Specifically, to guarantee uniqueness of the solution for the
matrix decomposition of Eq. 4, the network topology needs to
satisfy some criteria [19]: (i) the connectivity matrix [A] must have
full-column rank. (ii) When a node in the regulatory layer is
removed along with all of the output nodes connected to it, the
Table 1. The description of samples in GSE2189.
Samples
Sample
replicates Treated time (hr) Treatment
4_Hr_+MGd 3 4 50 uM MGd
12_Hr_+MGd 3 12 50 uM MGd
24_Hr_+MGd 3 24 50 uM MGd
4_Hr_No_MGd 3 4 5% mannitol
12_Hr_No_MGd 3 12 5% mannitol
24_Hr_No_MGd 3 24 5% mannitol
doi:10.1371/journal.pone.0031984.t001
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that still has full-column rank. (iii) [P] must have full row rank.
The NCA algorithm implemented in MATLAB by the authors
is downloadable at http://www.seas.ucla.edu/˜liaoj/. In this
study, we followed the manual of this package.
Pathway Enrichment Analysis
Pathway information was collected from KEGG (Kyoto
Encyclopedia of Genes and Genomes), a collection of online
databases dealing with genomes, enzymatic pathways, and
biological chemicals [20]. DAVID [21], a high-throughput and
integrated data-mining environment, was utilized to analyze gene
lists derived from high-throughput genomic experiments. Signif-
icant pathways that have at least two members and p-value ,0.1
were thus selected.
Pathway Crosstalk Analysis
PPI data were collected from the HPRD [22] and BIOGRID
[23]. A total of 326119 unique PPI pairs were collected to
construct the PPI network. Limma eBayes method [16] was used
to measure the differential expression status of genes. Pearson
correlated coefficient test was employed to determine the co-
expressed significance of each gene pair. The above two types of
values were mapped to the nodes and edges in the PPI network.
The following formula was used to define a function as the
combination of statistical significance of an interaction by a
scoring scheme [24]. The detail could be seen in Liu et al [14].
S(e)~f(diff(x), corr(x,y), diff(y))
~{2
Xk
i~1 loge(pi)
The diff(x) and diff(y) are differential expression assessments of
gene x and gene y, respectively. Corr(x’ y) represents the
correlation between gene x and gene y. f is a general data
integration method that can handle multiple data sources differing
in statistical power. Where k=3, p1 and p2 are the p-values of
differential expression of two nodes, and p3 is the p-value of their
co-expression.
To define the interaction significance between pathways, we
summarized all the scores of edges S(e) of all non-empty overlaps.
Specifically, the interaction score between two pathways was
estimated according to their overlapping status of weighted
pathways in the following formula:
C(pi, pj)~
X
e[Oij
S(e)
where Pi and Pj are two pathways and Oij is their overlapping. To
estimate the significance of the overlapping between different
pathways, we randomly sampled 1610
6 times of the two same size
pathways in the edges of pathway network and calculated their
overlapping scores. The frequency larger than a C score denoted
significant interaction between Pi and Pj.
Results and Discussion
Transcription Factor Activities
The schematic of our approach was shown in Figure 1. Based
on NCA method, 16 TFs were screened to construct a dynamic
regulatory network. Figure 2A and 2B showed the estimated
activities of the 16 TFs. Transcription factor activities clearly
showed early-, mid-, and late-phase action in response to MGd.
SP1, RARA, RELA, TP53, ETS1, and SMAD3 were activated
within 4 hours after the MGd was injected. SP1 activation peaked
at 4 hours and HIF1A, CREB1 and SPI1 were predicted to be
somewhat deactivated over 12 hours (Figure 2A). Research found
that Sp1 level accumulated strongly in early stage and then
declined in late stage [25] and Aryl hydrocarbon receptor in
association with RelA modulates IL-6 expression in non-smoking
lung cancer [26]. These are evidence which could improve the
reliable of research.
The calculated transcription factor activities were compared
with the gene expression data for each transcription factor
(Figure 2B).TP53, SMAD3, and HIF1A showed strong positive
correlation between activities and expression (correlation coeffi-
cient r.0.8) (Figure 2B). However, transcription factor activities
were sometimes, but not always, correlated with the gene
expression of the TFs.
We also compared the significant correlation between tran-
scription factor activities with published protein-protein interac-
tions catalogued in the HPRD [22] and BIOGRID [23].
Interestingly, TFs known to act together showed high correlation
in their activity profiles (Figure 2C). For example, the highly
correlated TFs SP1 and RELA regulated their target genes
together [27].
Our results also revealed several interactions between TFs
(Figure 2D). The transcription factor Sp1 regulates expression of
numerous genes involved in various cellular processes, and
dysregulation of Sp1 is observed in many cancers and diseases
[28]. Involvement of ESR1 in lung cancer has also been observed
[29]. Interaction of SP1 with ESR1 has been demonstrated in
breast cancer cells [30]. In addition, E2F1 and SP1 participate in
cell proliferation and viability via regulating phosphocholine
cytidylyltransferase alpha (CCTa) [31]. Thus the predicted
ESR1/Sp1 and E2F1/Sp1 interactions may suggest their regula-
tion role in the pathogenic process. Estrogen stimulation can
enhance the c-MYC-ESR1 interaction and facilitate the associa-
tion of ESR1, c-MYC, and the co-activator TRRAP with these
estrogen-responsive promoters, resulting in chromatin remodeling
and transcription increase in breast cancer. These suggest ESR1
and c-MYC may physically interact to stabilize the ESR1-
coactivator complex, thereby permitting other signal transduction
pathways to fine-tune estrogen-mediated signaling networks [32].
C-Myc, an oncogene, has also been demonstrated to interact
specifically with Smad3, one of the signal transducers involved in
TGF-b signaling which is involved in cancer development [33]. As
for NFKB1/RELA, NFKB1 or NFKB2 could bind to RELA,
RELB or REL to form the NFKB family of TFs. These hetero-
dimers participate in controlling a wide variety of genes, and are
important in embryonic development, apoptosis, immune, inflam-
matory and stress responses. The NFKB1/RELA complex is the
most abundant form of NFKB. In HeLa cells, RELA phosphor-
ylation could result in increased transcription of NFKB target
genes and inhibiting apoptosis [34].
Significant Regulation Relationships between TFs and
Target Genes
In Figure 3A, target genes were hierarchically clustered with the
adjusted strengths of TFs and shown with gene expression. We
identified several major clusters, which were correlated to the
coordinated action of TFs to regulate gene expression. We found
that MYBL2, DDX11, LAMP1, ETV4, and BMP4 were
regulated by MYC and ETS1. The MYC independently regulated
BAZ1B, ZFP36L2, DPM2, TSC2, ZNF274, and STAT6.
MYOD1 and ACP5 were regulated by the NFKB1. APEX1
Lung Cancer Dynamic Network and Pathway Crosstalk
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were hierarchically clustered with the expression of TFs Figure 3B.
Some of them in Figure 3B haven’t been emerge in Figure 3A.
The clusters shown in Figure 3A suggested that we might be able
to use our cluster information to discover new regulatory
relationships.
We found five significant regulation relationships which were
proved by the previous research: BMP4/Est1, TSC2/myc, APE1/
Sp1/p53, RARA/HOXA1, and SP1/USF2. BMP4 signaling
induces senescence and modulates the oncogenic phenotype of
lung cancer cell [35]. BMP4 promoter has two Ets-1 binding sites,
and Ets-1 activity is increased in hepatocellular carcinoma cells
under hypoxic conditions. Thus over-expression of Ets-1 markedly
enhances BMP4 promoter activity [36]. In addition, BMP4 is
associated with Smad and p38 MAPK pathway in lung cancer cell,
which was also observed in our regulatory network [28].
MYC could directly affect transcription of tuberous sclerosis 2
(TSC2), as shown by quantitative mRNA analyses and by Myc
binding to its promoter in chromatin immunoprecipitation assays.
Importantly, myc-null experiments have shown that Myc acts as a
strong and direct repressor for TSC2 expression because its loss
results in increased TSC2 mRNA. This finding shows that
regulation of TSC2 may contribute to the effects of MYC on
cell proliferation and neoplastic growth [37,38].
The putative promoter region of the Apex1 gene contains
CCAAT boxes and a CpG island possessing putative binding sites
Figure 1. Flowchart of dynamic transcriptional regulatory network construction.
doi:10.1371/journal.pone.0031984.g001
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transcription start, together with an adjacent CCAAT element,
establishes a protein-DNA complex required for basal transcrip-
tion of APEX1 [40]. Further study indicates that p53 provides a
mechanism for the down-regulation of APE1 by interfering with
Sp1 binding to the APEX1 promoter. These findings demonstrates
that p53 is a negative regulator of APE1 expression in response to
DNA damage [41].
RARA is one ligand dependent inducible transcription factor.
The RARs family can activate gene expression directly through
RA responsive elements (RAREs) localized in their target genes.
Functional RAREs are currently known for only a few HOX
genes, including HOXA1, HOXB and HOXC [42].
As a member of the bHLH family, USF-2 has been
demonstrated to specifically bind with E-box motif A, located
between 2147 and 2142 in the human [Arginine]vasopressin
Figure 2. Transcription factor activities calculated using NCA. (A) Predicted activities of the 16 TFs used in this study. Rows represented
progression in time and columns corresponded to the activities. Activities of each column were normalized to the zero time point. (B) Transcription
factor activities (blue) compared with gene expression (green), with Pearson correlation coefficients noted. Both activity and expression at each time
point were averages normalized to the time zero values. (C) Correlation matrix between transcription factor activities. Red represented positive
correlation and blue represented negative correlation. (D) Inferred combinatorial regulation pairs of TFs. Green solid line indicated that the pair was
supported by protein-protein interaction information from HPRD, BIOGRID and high correlation of their activities (.0.6). Black solid line indicated that
the pair was only supported by high correlation, and a green dotted line indicated that the pair was only supported by the interaction database.
doi:10.1371/journal.pone.0031984.g002
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However, there was evidence that a physical interaction between
USF2 and Sp1/Sp3 [45], suggesting USF-2 may exert important
roles in lung cancer through interaction with E-Box or GC box.
Overall Regulatory Dynamics in Response to MGd
We built an integrated dynamic model of the human lung
cancer in response to MGd (Figure 4), which consisted of the
calculated transcription factor activities, transcription factor
regulatory influences on each gene, subcellular location, and the
gene expression data. During the first 4-hour period, TP53, SP1,
E2F1, ETS1, SMAD3 and RELA were activated and interacted to
regulate gene expression. These TFs had already affected gene
expression including the genes in the Nucleus and Cytoplasm after
4 hours. SMAD3, also expressed in the Nucleus and Cytoplasm,
showed peak activity at 12 hours and then at 24 hours returned to
the previous 4 hours level. By contrast, E2F1 activation rapidly
returned to the base level of activity.
Pathway Crosstalk Analysis
Most of the significant pathways (p-value ,0.1 using the
hypergeometric test) were cancer related signaling pathways
(Table 2), including Pathways in cancer, Small cell lung cancer,
Non-small cell lung cancer, Pancreatic cancer, Jak-STAT signal-
ing pathway, PPAR signaling pathway and so on. These pathways
have been demonstrated involved in lung cancer in previous
works. For example, BMP4 treatment (enriched in the Pathways in
cancer) has been suggested to induce a senescent morphology in
Figure 3. Hierarchical clustering in the context of a defined regulatory network. (A) The adjusted strength matrix was used for clustering,
with the gene expression matrix appended. Four major clusters, which have more than three associated genes, were highlighted. In the adjusted
strength matrix heatmap, white indicated a weak regulatory influence. (B) Clustering with gene expression.
doi:10.1371/journal.pone.0031984.g003
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and activators of STAT6 (enriched in the Jak-STAT signaling
pathway) may transcriptionally up-regulate cyclooxygenase-2
expression and protect against apoptosis in NSCLC cells [46].
PPARc has been suggested to modulate the proliferation and
apoptosis of lung cancer cell through interaction with its ligand.
PPARc expression is found higher in lung cancer cell patients
when compared with normal surrounding tissue. The treatment of
lung adenocarcinoma cells (A549) with troglitazone (a PPARc
ligand) can enhance PPARc transcriptional activity and induce a
dose-dependent inhibition of A549 cell growth [47,48,49]. In brief,
activation of PPARc impedes lung tumor progression and PPARc
ligands may serve as potential therapeutic agents for lung cancer.
In this study, we found PPAR signaling pathway was an important
pathway in response to MGd-treatment, suggesting MGd may be
one potential PPARc ligand as troglitazone.
Figure 4. A dynamic network of transcription in response to MGd. Target genes were noted with circles, and TFs with triangle. The 4
subcellular locations (Nucleus; Cytoplasm; Plasma membrane; Extracelluar) were grouped in 4 cycles. Green dotted lines denoted of a target gene
which may transfer between two subcellular locations. Red and blue lines showed the influence of a transcription factor on a target gene.
doi:10.1371/journal.pone.0031984.g004
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a C score of each pair of pathways. PPAR signaling pathway
(hsa03320) was found cross-talking with the pathway of Non-
small cell lung cancer (hsa05223; p-value=0.056135), Pancreatic
cancer (hsa05212; p-value=0.056145), Bladder cancer
(hsa05219; p-value=0.056165), Adipocytokine signaling pathway
(hsa04920; p-value=0.056214), and Chronic myeloid leukemia
(hsa05220; -value=0.056214) after 4-hour MGd treatment
(Figure 5). But this crosstalking was not significant at the 12-
hour and 24-hour stages with the p-value .0.1.
Overall, we suggest PPAR signaling pathway (hsa03320) plays
an important role in the pathways crosstalk.
There was evident of interaction relationship between PPAR
signaling pathway and Adipocytokines signaling pathway in
previous study [50,51]. Among them, adipocytokines, secreted
from adipocytes, such as tumor necrosis factor-alpha (TNF-a),
plasminogen activator inhibitor type 1 (PAI-1), interleukin 6 (IL-6),
leptin, resistin, and adiponectin, play a significant role in normal
metabolic homeostasis and in the development of several diseases.
Leptin could be decreased regulation by PPAR-c agonists. PPAR-
c and liver receptor homolog-1 (LRH-1) play significant roles in
adiponectin transcriptional activation by means of PPRE and
LRH-RE in its promoter [50,51].
However, there are still some limitations in our research. Our
study is based on an assumption that mRNA expression levels are
controlled entirely by transcriptional regulation. However, mRNA
stability is also a less informative factor to the mRNA expression
levels [52,53]. If an mRNA whose expression level is determined
by mRNA stability can also express in the control cells, we can
exclude the influence of mRNA stability by comparison when their
degradation rates are similar. If such an mRNA cannot express in
the control cells, we ignore the mRNA stability. This may bring
systematic errors to this study. In addition, the quality and
quantity of Protein-protein interaction (PPI) data is one of the
problems for the PCA. PCA was based on a PPI interaction data
[24]. Protein-protein interactions provide valuable information
about how genes carry out their biological functions. It is expected
that protein-protein interaction data information will be widely
accessible in the near future by using various experiment methods.
Conclusion
We managed to interpret the molecular mechanism of lung
cancer from a systematic and dynamic perspective by NCA. We
took the control strength (only as positive or negative) as the
regulatory relationships between TFs and their target genes
(including TFs), and the TFs activities was substituted for their
Table 2. Significant pathways.
Pathway ID Description P-value
hsa05200 Pathways in cancer 2.97E-07
hsa05222 Small cell lung cancer 1.55E-04
hsa05223 Non-small cell lung cancer 3.28E-04
hsa05212 Pancreatic cancer 9.85E-04
hsa05215 Prostate cancer 0.002168
hsa05221 Acute myeloid leukemia 0.005524
hsa04110 Cell cycle 0.007346
hsa05220 Chronic myeloid leukemia 0.011247
hsa05216 Thyroid cancer 0.014013
hsa04630 Jak-STAT signaling pathway 0.015367
hsa05219 Bladder cancer 0.028249
hsa05214 Glioma 0.059075
hsa04920 Adipocytokine signaling pathway 0.065857
hsa03320 PPAR signaling pathway 0.069342
hsa05218 Melanoma 0.072888
doi:10.1371/journal.pone.0031984.t002
Figure 5. Dynamic of pathway-crosstalk. The red line indicated the p-value of cross-talking between two pathways less than 0.1. The blue line
indicated the cross-talking was not significant with the p-value large than 0.3.
doi:10.1371/journal.pone.0031984.g005
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the significant TFs and their target genes were detected, the
control strength of TFs to their target genes was recalculated, and
the activities of the TFs were estimated.
NCA and PCA methods were applied to explore the
transcription response mechanism in MGd-treated human lung
cancer cells based on the assumption that lung cancer is a
contextual attribute of distinct patterns of interactions between
multiple elements. The results identified a set of key TFs, target
genes for these TFs and signaling pathways involved in regulatory
networks. Through the activity of TFs, we found that transcription
factor activities clearly showed early-, mid-, and late-phase action
in response to MGd. We also identified several major clusters,
which were correlated to the coordinated action of TFs to regulate
gene expression. Besides, pathway-crosstalk analysis indicated
there was an interaction relationship between PPAR signaling
pathway and Adipocytokines signaling pathway in our study.
Finally, an integrated dynamic model of the human lung cancer
was built in response to MGd (Figure 4), which consisted of the
calculated transcription factor activities, transcription factor
regulatory influences on each gene, subcellular location, and the
gene expression data.
The development of new high-throughput technologies greatly
produces great amounts of biology data. Then how to mine
meaning information from the data become necessary. Our studies
revealed that NCA and PCA could be successfully applied for
inferring the transcriptional regulatory network of MGd-treated
human lung cancer.
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